Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolyPid Ltd PYPD

Healthcare Biotechnology
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Recent & Breaking News (NDAQ:PYPD)

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

GlobeNewswire October 4, 2023

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 22, 2023

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

GlobeNewswire September 21, 2023

PolyPid Announces Reverse Share Split

GlobeNewswire September 20, 2023

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

GlobeNewswire September 19, 2023

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 9, 2023

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

GlobeNewswire July 26, 2023

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

GlobeNewswire June 29, 2023

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

GlobeNewswire June 22, 2023

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

GlobeNewswire June 5, 2023

PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

GlobeNewswire May 22, 2023

PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

GlobeNewswire April 26, 2023

PolyPid to Participate in Upcoming Investor Conferences

GlobeNewswire April 24, 2023

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

GlobeNewswire April 14, 2023

PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds

GlobeNewswire March 31, 2023

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

GlobeNewswire March 29, 2023

PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire March 28, 2023

PolyPid to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 7, 2023

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire February 8, 2023